Martin Dreyling

Martin Dreyling, MD is Professor of Medicine and Head of the Department of Haematology and Oncology at University Hospital Munich, Ludwig Maximilian University, where he leads one of Europe's most productive lymphoma clinical trial programs. He is internationally recognized as the foremost expert on mantle cell lymphoma (MCL), having led the pivotal TRIANGLE trial — a three-arm phase III study of the European MCL Network published in Nature (2022) — which demonstrated that adding ibrutinib to standard immunochemotherapy with or without autologous stem cell transplantation (ASCT) substantially improved failure-free survival and overall survival in previously untreated younger MCL patients. Crucially, TRIANGLE showed that ibrutinib-based chemoimmunotherapy without ASCT achieved outcomes comparable to the transplant-containing arm, fundamentally challenging the role of upfront ASCT and reshaping treatment standards for MCL globally. Dr. Dreyling has been a founding member and scientific committee chair of the European MCL Network and has designed numerous earlier MCL trials evaluating rituximab maintenance, cytarabine-containing induction regimens, and bendamustine-rituximab. Beyond MCL, he has contributed to PI3K inhibitor development in follicular and marginal zone lymphoma and serves as a principal author of ESMO clinical practice guidelines for MCL and indolent NHL.